BMRA · Biomerica Inc
$1.71
-0.01 (-0.51%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Oct 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about our ability to continue as a going concern within twelve months following the issuance date of these financial statements. Our future viability depends on the successful execution of our strategic plans, securing additional near-term financing, and achieving profitable operations.”View the 10-Q filed Oct 15, 2026
Market Cap
$7.86M
Shares
4.60M
Volume · Oct 21
7547
Avg daily vol (3M)
70.76K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.71
Open$1.69
Day$1.60–1.72
52W close$1.49–3.20
Avg vol 30d21K
Short int28K · 0.6% float · 1.0d
Short vol54%
DataJan 2020–Oct 2026
Filing10-Q · Oct 15
Up next
filed Oct 15, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$4.34M
Trailing 12 months
Net income (TTM)
−$5.01M
Trailing 12 months
Revenue growth YoY
-8.3%
Year over year
Operating margin
-125.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$2.73M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+24.9%
Year over year · more shares
Price change (1Y)
-44.9%
Trailing year
Short interest
0.6%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−18%
below
Price vs 50-day avg
−16%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
13%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−34%
trailing
6-month return
−22%
trailing
YTD return
−32%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+82% holders QoQ · +9 funds added
Insider flow
Accumulating
Net +$158.0K over 90 days · 0% sells
Short interest
Falling
0.60% of float · ▼ -25.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
20 holders — mid 3-yr range
Squeeze score
25
low risk · 0–100
Fundamentals
Revenue growth
−16%
Y/Y
Gross margin
8%
contracting
EPS growth
+40%
Y/Y
Free cash flow
$-3.5M
Quant / Vol
risk profile
Volatility
58%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
7.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−18%
Bearish
Price vs 50-day avg
−16%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
13%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+82% holders QoQ · +9 funds added
Insider flow
Accumulating
Net +$158.0K over 90 days · 0% sells
Short interest
Falling
0.60% of float · ▼ -25.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
20 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 13%
Range high $3
vs 200-day avg -18%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BMRA
this stock
Biomerica Inc
|
$7.86M | -32.1% | -16.2% | — | 0.6% |
|
ABT
Abbott Laboratories
|
$171.24B | -19.8% | +5.7% | 31.8 | 0.8% |
|
MDT
Medtronic plc
|
$121.04B | -3.2% | +8.4% | 23.3 | 3.1% |
|
SYK
Stryker Corp
|
$116.76B | -15.3% | +11.2% | 31.5 | 1.5% |
|
BSX
Boston Scientific Corp
|
$64.51B | -53.3% | +12.5% | 18.0 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
SEC Filings
Latest
DEF 14A
- Filed
- Oct 16, 2026
- This year
- 11
Biomerica's proxy statement seeks stockholder votes at its December 11, 2026 annual meeting to elect five directors, ratify Haskell & White LLP for the fiscal year ending May 31, 2027, and amend the 2024 Stock Incentive Plan to add 150,000 shares.
ViewEarnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BMRA | -5.0% | -34.5% | -21.6% | -24.3% | -32.1% |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | -5.5% | -35.2% | -29.1% | -25.7% | -45.5% |